论文信息 - 610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations - 字舞流文

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

N. Agarwal | C. Corcoran | O. Sartor | M. Hussain | D. Olmos | K. Fizazi | A. Thiery-Vuillemin | K. Chi | J. Mateo | S. Sandhu | N. Shore | C. Adelman | P. Twardowski | M. Ozguroglu | J. Burgents | Jinyu Kang | F. Saad | C. Gresty | Carrie A. Adelman | J. D. Bono | Guilhem Roubaud | Antoine Thiery-Vuillemin | Mustafa Ozguroglu | Joseph Burgents | G. Roubaud